Isarna Therapeutics GmbH

Isarna Therapeutics GmbH is a clinical-stage biotechnology company based in Gräfelfing, near Munich, Germany.

The company specializes in developing next-generation antisense oligonucleotide therapies that target TGF-β signaling pathways. These therapies aim to treat retinal diseases, fibrotic liver conditions, and cancer. Isarna is led by experienced executives, including COO Dr. Rene Rückert and CMO Prof. Marion Munk, and is currently preparing for Phase 2a studies. The company's lead product, ISTH0036, is designed to selectively inhibit TGF-β2 mRNA and protein, showing promising safety and efficacy in early trials. Isarna's pipeline includes additional assets targeting various TGF-β isoforms for conditions such as liver cancer and nonalcoholic steatohepatitis (NASH). The company focuses on advancing its proprietary antisense agents and is actively seeking partnerships and investment to support its clinical development efforts.